Trimodal or bimodal age-specific incidence rates for Burkitt lymphoma (BL) were observed in the U.S. general population, but the role of immunosuppression could not be excluded. Incidence rates, rate ratios (IRR), and 95% confidence intervals (95% CI) for BL and other non-Hodgkin lymphoma (NHL), by age and CD4 lymphocyte count categories, were estimated using Poisson regression models using data from the U.S. HIV/AIDS Cancer Match study . BL incidence was 22 cases per 100,000 person-years and 586 for non-BL NHL.
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Background
Burkitt lymphoma (BL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) with three clinical variants: endemic (eBL), sporadic (sBL), and acquired immunodeficiency-associated BL (aBL) 1 . These clinical variants, which are defined, in part, by where they occur geographically, are histologically indistinguishable 1 and their etiology is incompletely understood 2 . Endemic BL occurs in children mostly as extranodal jaw or orbital masses in equatorial Africa and Papua New Guinea 3 . Sporadic BL occurs anywhere in the world at any age mostly with abdominal or nodal involvement [4] [5] . Immunodeficiency-associated BL is diagnosed in people with human immunodeficiency virus (HIV) 1 , among whom it is often the first indication of AIDS onset at least in the West. Risk for both eBL and sBL appears to be highest at age 5-9 years and sBL rates are also elevated at the oldest ages 4, 6 . Because BL is a rapidly growing tumor, doubling its cell mass about every 1-2 days 7 , the interval from trigger to diagnosis may be relatively short, so study of age-specific risk may provide etiologic information.
In an assessment of age-specific risk for BL in the United States, using data from the National Cancer Institute's Surveillance, Epidemiology and End
Results (SEER) Program (1973 Program ( -2005 , we observed three incidence peaks near ages 10, 40, and 70 years among males and two peaks near ages 10 and 70 years among females for both Whites and Blacks. However, the role of AIDSrelated immunosuppression could not be excluded 9-10 because we were not able to separately analyze AIDS and non-AIDS BL. To address this limitation, we investigated age-specific BL incidence among persons with AIDS (PWA) in the For personal use only. on October 31, 2017. by guest www.bloodjournal.org From U.S. Because age is a surrogate for cumulative exposure to deleterious infections a linear increase in risk for BL with age in PWA would suggest cumulative impact of deleterious infections given immunosuppression, whereas a non-linear risk increase would suggest that age may be a surrogate for differences in the etiology or biology of BL diagnosed at different ages that occur independent of immunosuppression 8 .
Methods
Data were obtained from the National Cancer Institute's U.S. populationbased HIV/AIDS Cancer Match (HACM) study [11] [12] [13] [14] . . Cases diagnosed during 0 to 3 months from AIDS diagnosis were categorized as prevalent; cases diagnosed from 4 to 60 months after AIDS diagnosis were considered incident. Prevalent cases were excluded from analyses because they may be biased by characteristics related to diagnosis of AIDS and/or survival up to AIDS. Incident cases were used in analyses because they are less biased and they allow inferences about the temporal relationship between risk factors associated with disease to be made. (0-19, 20-31, 32-39, 40-51, 52-59, >60 years) , and calendar-year of AIDS diagnosis (1980-1989, 1990-1995, and 1996-2005) . We used the most recent value for CD4 lymphocyte count at AIDS during six months before to three months after AIDS diagnosis. Calendar-year period reflected progressive improvement in anti- , we plotted age-specific incidence rates for BL by six age groups on a log (y) and linear (x) scale, such that a slope of 10 degrees equaled a 1% per year change in rates 17 , to assess whether trimodal age-specific patterns were present in immunosuppressed persons. We also plotted log BL incidence by four CD4 lymphocyte groups to explore the risk patterns with immunosuppression, given that BL occurs over a wide range of CD4 lymphocyte counts. Log incidence rates for other NHLs were plotted by age and CD4 lymphocytes for comparative purposes. Analyses were performed using the SAS, version 9.1 (SAS Institute Inc, Cary, North Carolina, USA).
Results
We analyzed 1,103 cases of BL, including 797 that were prevalent and 306 that were incident, among 567,865 PWA followed for an average of 2.4 years. By comparison, we identified 15,730 other NHLs, including 7,580 prevalent and 8,150 incident cases, during the same follow-up period. The mean ages for prevalent and incident BL were similar (38.3 versus 38.5 years, p=0.48).
In contrast, the mean age for prevalent other NHLs was on average three years For personal use only. on October 31, 2017. by guest www.bloodjournal.org From younger than the mean age for incident other NHLs (38.1 years versus 41.1 years, p<0.001). Table 1 shows the demographic characteristics of PWA studied, the numbers of incident BL, the crude incidence rates, and the crude and multivariate-adjusted incidence rate ratios (aIRR). As expected, most BL (89.2 %) were aged 20-51 years, and only 3.3% were aged <20 years and 7.5% were aged 52 years or older.
Overall BL incidence was 22.0 per 100,000 persons ( Table 1 ). The crude and adjusted incidence rate ratios were different for some variables, suggesting confounding was present, so both the crude and adjusted incidence rate ratios are reported ( Table 1 ). The crude male to female IRR was reduced from 2 to 1.6 (95% CI 1.1-2.3) in the adjusted model, and the aIRR was lower in non-Hispanic Black than non-Hispanic White PWA (0.4, 95% CI 0.3-0.5). Compared to MSM, the crude BL incidence rates were lower in PWA whose HIV transmission risk category was IDU or heterosexual, but the differences became non-significant in multivariate-adjusted analysis. Compared to PWA aged 32-39 years, the crude IRR for BL was non-significantly elevated among PWA aged 0-19 years (1.6, 95% CI 0.8-3.0), but it became significant in multivariate analysis (2.3, . The crude and adjusted IRR for BL among PWA aged 20-31 years were significantly decreased (both 0.6, 95% CI 0.4-0.8), but the crude and adjusted IRR for BL among PWA aged 40-51 years, 52-59 years and those aged 60 years or older were not significantly different. The crude and adjusted IRR for BL were notably lower among PWA having <50 CD4 lymphocyte cells/µL than those with >250 cells/µL at AIDS (aIRR 0.3, 95% CI 0.2-0.6). The BL rate among PWA declined over time from 1980-1989 to 1996-2005. The age-specific incidence rates for BL suggested three peaks during the pediatric, adult, and geriatric years, although the adult confidence limits overlapped ( Figure 1, Panel A) . In contrast, age-specific incidence rates for other NHLs increased from childhood to adulthood and stabilized thereafter ( Figure 1A 
Discussion
The major findings were bimodal and perhaps trimodal age-specific BL incidence peaks, significant decline in BL risk at low CD4 lymphocyte counts at AIDS, and lack of association between risk for BL and HIV transmission risk categories, which are a surrogate for sexual and blood-borne infections that are highly prevalent in the US HIV/AIDS population. Our finding of bimodal or trimodal BL incidence peaks in PWA replicates our results in the U.S. general , whose risk for BL is lower, or to access to HAART after 1996. In the HACM study, the proportion of Blacks, who have a lower risk for BL compared to Whites, increased from 30% in 1980-1989 to 39% in 1990-1995 to 50% in 1996-2005 . Conversely, the proportion of Whites, whose risk for BL is higher than Blacks, decreased from 54% in 1980-1989, to 41% in 1990-1995 and to 29% in 1996-2005 . Possibly, the paradoxical relationship between risk for BL and CD4 lymphocyte counts may be a clue to a physiological role of functional CD4 lymphocytes in BL lymphomagenesis. . Non-specific disruption of B-cell production, however, is unlikely to be the explanation, given the continuing risk of other B-cell NHLs at low CD4 lymphocyte counts.
Our study is the largest to assess age-specific incidence of BL among persons with AIDS. Even so, the small number of cases in some categories, such as age groups 52-59 years and >60 years, prevented us from obtaining stable estimates of fluctuating risk with age to definitively show trimodality. Lack of centralized tumor pathology review is a limitation, however, misclassification of For personal use only. on October 31, 2017. by guest www.bloodjournal.org From unlikely to explain the results. We lacked CD4 lymphocyte counts after AIDS, thus, patterns of CD4 lymphocyte counts at BL, which may be more relevant to etiology could not be assessed.
To summarize, BL among PWA in the U.S. was characterized by at least two and perhaps three age-specific incidence peaks, suggestive of bimodality and perhaps trimodality, and BL incidence declined at low CD4 lymphocyte counts, suggesting functional CD4 lymphocytes may be required for BL to develop.
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